MedPath

The Effect of a Probiotic Strain on Ibuprofen-induced GI Damage

Not Applicable
Completed
Conditions
Reduction of Small Intestinal Ulceration Risk
Interventions
Other: Placebo
Dietary Supplement: Bif195
Registration Number
NCT04447924
Lead Sponsor
Chr Hansen
Brief Summary

To investigate if a daily dose of minimum 15 billion CFU of Bif195 reduces the risk of small-intestinal tissue damage in an Ibuprofen challenge model as assessed by video capsule endoscopy in a healthy US population.

Detailed Description

This trial is a single-site, randomized, double-blind, placebo-controlled, two-armed, parallel-group trial in healthy volunteers aged 18 - 40 years. The trial will investigate the effect of daily intake of the probiotic strain Bif195 or placebo when co-administered to daily intake of 800mg of Ibuprofen.

The trial includes a run-in period of two weeks duration followed by a six weeks intervention period where Bif195/placebo and Ibuprofen is co-administered.

Subjects will participate in the trial for a total duration of 8 weeks including the run-in phase. Besides the screening visit, the trial will consist of 5 visits.

After having given their written informed consent, subjects will complete the screening procedures to evaluate their eligibility for participation in the trial and complete a run-in period of two weeks duration to washout possible pre-trial probiotics and/or use of medication. After baseline assessments at Visit 2, subjects will start daily intake of 800mg of Ibuprofen and also be randomly assigned to 6-weeks daily intake of Bif195 or placebo product in a ratio of 1:1.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
177
Inclusion Criteria
  • Written informed consent
  • Healthy and without any gastrointestinal pain or other significant symptoms
  • Age 18 - 40 years
  • Willing to abstain from any other probiotic products and/or medication known to alter gastrointestinal function throughout the participation of the trial
Exclusion Criteria

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo armPlaceboPlacebo arm. Similar trial product, but without Bif195 bacteria
Bif195 armBif195Active trial product with minimum 15 billion CFU daily dose
Primary Outcome Measures
NameTimeMethod
Lewis score area-under-the-curve for Bif195 vs Placebo6 weeks

The effect of Bif195 versus placebo on small intestinal mucosal damage during a 6-week Ibuprofen challenge measured as the area-under-the-curve of the Lewis scores obtained from all video capsule endoscopies between Visit 2 (randomization) and Visit 6 (end of treatment).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Atlantia Food Clinical Trials

🇺🇸

Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath